VEC.L Share News (VEC)

LONDON MARKET MIDDAY: Risk-Off Mood Hits Stocks As Bond Yields Shrink

WINNERS & LOSERS SUMMARY: Vectura Shares Rise After Skyepharma Tie Up

Allergy Therapeutics Appoints Skyepharma's Wykeman As Finance Director

Vectura-Skyepharma Merger Completed As Scheme Becomes Effective (ALLISS)

Vectura Says VR942 Asthma Treatment Phase-One Trials Meet Objective

Vectura reports strong rise in full-year earnings

(ShareCast News) - Vectura´s full-year results edged past forecasts with analysts noting the sharp improvement in its free-cash-flow generation even as they pointed out several potential share price drivers which were looming increasingly closer on the horizon. The manufacturer of airways diseases t

Vectura Sees Narrowed Loss Ahead Of Skyepharma Deal Completion

Vectura teams up with Propeller on inhaler plan

(ShareCast News) - Vectura Group said it was joining forces with Propeller Health to develop inhalers that combine their two technologies. In a statement, Vectura said the plan was to use its dry powder inhaler technology with Propeller's FDA-cleared digital health platform to treat respiratory dise

Vectura Teams Up With Propeller Health To Combine Technology

Vectura Says Skyepharma Deal To Complete By June 10

Earnings, Trading Statements Calendar - Week Ahead

Skyepharma Says Trading Good, Anticipates Full-Year Revenue Growth

Vectura, Skyepharma Merger Cleared By UK Competition Authority

Drug trials using Vectura's Fox nebuliser make progress

(ShareCast News) - A respiratory treatment being developed using Vectura's Fox nebuliser technology device has passed safety and efficacy trials and looks likely to be moved into a Phase II efficacy study in infants. Drug developer Ablynx has published positive results from first-in-infant Phase I/I

AGM, EGM Calendar - Week Ahead